1960results about "Hydrolysed protein ingredients" patented technology

The invention relates to libraries of synthetic test compound attached to separate phase synthesis supports. In particular, the invention relates to libraries of synthetic test compound attached to separate phase synthesis supports that also contain coding molecules that encode the structure of the synthetic test compound. The molecules may be polymers or multiple nonpolymeric molecules. Each of the solid phase synthesis support beads contains a single type of synthetic test compound. The synthetic test compound can have backbone structures with linkages such as amide, urea, carbamate (i.e., urethane), ester, amino, sulfide, disulfide, or carbon-carbon, such as alkane and alkene, or any combination thereof. Examples of subunits suited for the different linkage chemistries are provided. The synthetic test compound can also be molecular scaffolds, such as derivatives of monocyclic of bicyclic carbohydrates, steroids, sugars, heterocyclic structures, polyaromatic structures, or other structures capable of acting as a scaffolding. Examples of suitable molecular scaffolds are provided. The invention also relates to methods of synthesizing such libraries and the use of such libraries to identify and characterize molecules of interest from among the library of synthetic test compound.

The present invention provides methods of improving the osteogenic and / or chondrogenic activity of a bone matrix, e.g., a dermineralized bone matrix (DBM), by exposing the bone matrix to one or more treatments or conditions. In preferred embodiments the bone matrix is derived from human bone. The treatment or condition may alter the structure of the bone matrix and / or cleave one or more specific proteins. Cleavage may generate peptides or protein fragments that have osteoinductive, osteogenic, or chondrogenic activity. Preferred treatments include collagenase and various other proteases. The invention further provides improved bone and cartilage matrix compositions that have been prepared according to the inventive methods and methods of treatment using the compositions. The invention further provides methods of preparing, testing, and using the improved bone matrix compositions. Ona assay comprises exposing relatively undifferentiated mesenchymal cells to a bone matrix composition and measuring expression of a marker characteristic of osteoblast or chondrocyte lineage(s). Increased expression of the marker relative to the level of the marker in cells that have been exposed to a control matrix (e.g., an inactivated or untreated matrix) indicates that the treatment or condition increased the osteogenic and / or chondrogenic activity of the bone matrix. Suitable cells include C2C12 cells. A suitable marker is alkaline phosphatase. The inventive methods increase the osteogenic and / or chondrogenic activity of human DBM when tested using this assay system.

A nutritional composition is described for prevention or treatment of an immune condition. The composition includes at least vitamin E, vitamin C, vitamin B6, folic acid, vitamin B12, copper, zinc, selenium, fructo-oligosaccharides and / or gum acacia, a probiotic lactic acid bacterium. For example, in an embodiment it comprises per 300 g: 150 IU Vitamin E, 120 mg Vitamin C, 2 mg Vitamin B6, 400 ug Folic acid, 3.8 ug Vitamin B12, 1.5 mg Copper, 15 mg Zinc, 100 ug Selenium, 3 g Fructo-oligosaccharides and / or gum acacia, 10E10 cfu ST11 lactobacillus. Also disclosed are a method for making the nutritional composition, a method for manufacturing a functional food or medicament; and a method of prevention or treatment of an immune condition by administering an effective amount of the composition, functional food or medicament.

The present invention provides a formulation for the delivery of bioactive constituents to biological surfaces, wherein said formulation comprises a suspension or solution of at least one isolated and purified casein protein or salt thereof, in water, together with at least one bioactive constituent.

An in vivo method for labelling a protein having an N-terminal cysteine is disclosed. A probe comprising a thioester group and a detectable label is introduced into a cell expressing the N-terminal cysteine protein, allowing for the N-terminal cysteine to cleave the thioester bond and resulting in the label being covalently attached to the N-terminus of the protein by an amide bond.

Disclosed are amphiphilic compounds comprising Formula I:wherein R1, R2, and R3 are C2-C12 straight or branched alkyl; unsubstituted phenyl, biphenyl, C3-C8 cycloalkyl, or C3-C8 cycloalkenyl; or phenyl, biphenyl, C3-C8 cycloalkyl, or C3-C8 cycloalkenyl substituted with one, two, or three C1-C6 straight or branched alkyl groups; or R1 and R2 combined are C3-C8 cycloalkyl, C3-C8 cycloalkenyl; or C3-C8 cycloalkyl or C3-C8 cycloalkenyl substituted with one, two, or three C1-C6 straight or branched alkyl groups; one of R4 or R5 is selected from the group consisting of C2-C6-straight or branched alkyl-(dimethyl-N-oxide), alkyl-(dimethylamine), alkyl-(trimethylammonium), alkyl-glucosyl, alkyl-maltosyl, glucosyl, maltosyl, and polyethylene(glycosyl); the other of R4 or R5 is selected from the group consisting of H, C2-C6 straight or branched alkyl or alkenyl, C2-C6-straight or branched alkyl-(dimethyl-N-oxide); alkyl-(dimethylamine), alkyl-(trimethylammonium), alkyl-glucosyl, alkyl-maltosyl, glucosyl, maltosyl, and polyethylene(glycosyl); and salts thereof. The compounds are detergents useful in the solubilization of membrane-bound proteins.

Embodiments relate to methods and compositions for eliciting, enhancing, and sustaining immune responses, preferably multivalent responses, preferably against MHC class I-restricted epitopes. The methods and compositions can be used for prophylactic or therapeutic purposes.

The invention relates to a method for enzymatically obtaining protein hydrolysates for human consumption, animal feed and cosmetics. The process involves the use of a proteolytic composition derived from fish, such as Cod (Gadus morhua), to obtain hydrolysates which have a non-bitter taste and retain the flavor and aroma of the protein-containing material which is hydrolyzed: e.g. when hydrolyzing protein-containing material from marine organisms or parts thereof, such as fish, shrimp, lobster or other seafood according to the invention, a protein hydrolysate is produced that has a characteristic natural flavor of the organism Also provided are food products comprising the hydrolysates of the invention, such as soup, sauce, cheese, HVP, meat extract and flavoring agent, broth, paté, mousse, frying dough, orly dough, and pastries.

Processing methods and compositions of matter are disclosed for lipid fractions of sea cucumber intestinal mass and body wall tissue suitable for the healthfood industry and aquaculture feed pigment industry. A process and composition of matter description for obtaining a high protein de-lipidized, de-odorized meal is also disclosed.

The invention relates to cosmetic or therapeutic compositions that contain hydrolysed yeast proteins as an active ingredient, to the use of said cosmetic or therapeutic compositions, and to a method for cosmetic treatment.

A hydrate of brain protein is prepared from pig's brain through adding purified water, homogenizing, heating, cooling, regulating pH=1.5-2.0, enzymolyzing, regulating pH=7.7-8.0, enzymolyzing, regulating pH=2.5-3.0 freezing, thawing, filter, regulating pH to become neutral, ultrafiltering, concentrating, sterilizing, adding amino acids, regulating peptide map, diluting, and steam sterilizing.

The present invention describes therapeutic compositions comprising one or more minerals, including trivalent iron, divalent manganese and salts thereof, suitable in facilitating synthesis and deposition of connective tissue matrix, particularly rich of elastin and collagen, and mitogenic potential in human dermal fibroblasts. It also describes the phenomenon in which stimulation of elastogenesis by arterial SMC associates with a net decrease in proliferation of these cell types. The present invention also describes methods of treatment of human skin fibroblasts and arterial smooth muscle cells. The therapeutic compositions of the present invention comprise one or more of trivalent iron or divalent manganese or salts thereof and may be combined with an elastic tissue digest.

The invention relates to functional peanut small molecule mixed polypeptide, a preparation method and application thereof, belonging to small molecule mixed polypeptide generated by peptide chain hydrolysis.The invention is characterized in that the functional peanut small molecule mixed polypeptide is prepared by adopting the following raw material components by weight part: 100 parts of defatted peanut cake, 6-10 parts of combined enzyme preparations, 6-12 parts of active carbon, 3-8 parts of diatomite, 3-8 parts of pearlite and 100 parts of water; and the following technical indexes are achieved: the molecular weight distribution range Dalton (D) is less than or equal to 3000, the content of the small molecule mixed polypeptide is more than or equal to 80wt, the total nitrogen is more than or equal to 12wt%, the water solubility is 90wt%, the water is less than or equal to 5wt%, and the fat is less than or equal to 0.5wt%.The invention provides a product of the functional peanut small molecule mixed polypeptide with high purity, good solubility, average molecular weight of less than 3000D and strong biological functionality and a preparation method of the functional peanut small molecule mixed polypeptide with short production cycle, high product yield and low preparation cost. The functional peanut small molecule mixed polypeptide is suitable for a raw material of medicines, health food and beverage and functional nutritious food.

Disclosed are infant formulas and corresponding methods of using them to promote retinal health and vision development in infants. The formulas, which are free of egg phospholipids and comprise fat, protein, carbohydrate, vitamins, and minerals, including docosahexaenoic acid and, on a ready-to-feed basis, at least about 50 mcg / liter of lutein, wherein the weight ratio of lutein (mcg) to docosahexaenoic acid (mg) is from about 1:2 to about 10:1. The formulas are also believed to be especially useful in reducing the risk of retinopathy of prematurity in preterm infants.

A method and pharmaceutical composition for ceasing milk production, for inducing involution, or for treating infection in a mammary gland of a lactating animal is described. The method is effected by direct administration of calcium chelators to the gland, or upon administration of enzymes which cause production of chelators in situ. The invention can be used to change the physiologic state of a single mammary gland of a lactating animal without significantly affecting the physiologic state of other mammary glands of the same animal. Changes resulting from use of the invention may be either transient or long lasting. The invention is expected to have uses in commercial agriculture and human medicine.

The invention relates to a food composition comprising an amino acid part having at least the amino acids leucine, isoleucine, valine, threonine and lysine in an amount of from about 35 to 90 g / 100 g of the total amount of the amino acid part as a method how to produce said food composition. The invention relates to different food products comprising said food composition.

The invention discloses novel plant small-molecule peptides, particularly relates to small-molecule peptides of a sunflower head as well as a preparation method and medical application of the small-molecule peptides, and further discloses medical application of the small-molecule peptides of the sunflower head to treatment of gout diseases. The small-molecule peptides of the sunflower head are low in molecular weight of proteins and can be directly absorbed by a human body without the digestion system; the peptides can be absorbed quickly and takes effect efficiently; a related extracting and separating process is simple and is easy to operate; no special equipment is required, and the cost is low; reagents used are pollution-free to the environment. The small-molecule peptides are suitable for large-scale industrial production.

Product R, a novel therapeutic composition for treating viral infections and stimulating the immune system, comprises nucleotides and peptides that have molecular weights not more than 14 KDa and substantially not more than 8 KDa. The composition has a light absorption spectrum with typical absorption ratios of 1.998 at 260 nm / 280 nm and 1.359 at 260 nm / 230 nm.

The invention provides a method of stimulating hair growth, comprising administering a therapeutic amount of a hydrogel matrix to an intradermal or subdermal site where hair growth is desired, the matrix composition comprising gelatin, such as denatured collagen, and a long chain carbohydrate, such as dextran. The matrix may further include polar amino acids, nitric oxide inhibitors and super oxide inhibitors. Injection is a preferred method of administration.

The invention provides a preparation method for a chlorella polypeptide microcapsule. The method comprises the following steps: extracting chlorella protein by using a low temperature ultrahigh pressure continuous flow cell crusher; hydrolyzing the chlorella protein with papain; filtering the hydrolyzed chlorella protein with an ultrafiltration centrifuge tube; then carrying out separation and purification by using ion exchange chromatography DEAE-52 and gel chromatography dextrangel G-25 columns; and finally utilizing complex coacervation to prepare the chlorella polypeptide microcapsule. The chlorella polypeptide microcapsule prepared in the invention has antitumor activity, e.g., the chlorella polypeptide microcapsule has inhibitory effects on in vitro growth of human hepatoma carcinoma cells HepG2 and the inhibition rate of the chlorella polypeptide microcapsule reaches 38% when concentration is 400 mu g / mL. Therefore, the chlorella polypeptide microcapsule prepared in the invention is beneficial for development and utilization of antitumor health food and medicinal products.

The present invention is directed to ophthalmic compositions containing protease-inhibiting peptide substrates. In a preferred embodiment, the protease-inhibiting peptide substrate is gelatin. The compositions may also contain a galactomannan. In a particularly preferred embodiment, the compositions contain gelatin, a galactomannan and a borate salt. The present invention also describes methods of use of these compositions to inhibit protease MMP-9, and methods of topical administration of the compositions to the eye, particularly for the treatment of dry eye.

The invention discloses a whey protein active peptide with antioxidant activity and a preparation method thereof. The preparation method comprises the following steps: (1) adding protease into whey protein solution for enzymolysis, wherein the enzymolysis temperature is 40-60 DEG C, and the pH value is 6.0-8.0; (2) after enzymolysis, inactivating the protease; (3) precipitating the whey protein not hydrolyzed in enzymolysis solution, and removing the whey protein to take supernatant; (4) carrying out ultrafiltration on the supernatant by an ultrafiltration membrane the cut-off molecular weight of which is less than or equal to 10,000 dalton, collecting filter liquor of peptide the molecular weight of which is less than or equal to 10,000 dalton; (5) concentrating the filter liquor; (6) desalting the concentrated liquor; and (7) concentrating the desalted solution, and then freezing and drying. In the invention, the obtained whey protein active peptide has significant antioxidant property and specific functional characteristics and stable quality, and can be widely applied to the fields of food, cosmetics, medicine and the like. The production technology is simple and is convenientfor scale production, the raw material whey protein has high use ratio, and the production cost is low.

The present invention relates to a kind of brain protein hydrolysate and the production process of its freeze dried preparation. The brain protein hydrolysate for injection is prepared with pig brain and through the steps of homogenating in a colloid mill to collect slurry, hydrolyzing with pepsase and pancreatin to collect supernatant, filtering with filer paper to collect filtrate, separating and purifying the filtrate with hydroxyapetite column, regulating peptide map and collecting object, ultrafiltering with membrane of intercepting molecular weight 8 KD to collecting filtrate, nitrogen and amino acid analysis and adding amino acid in the required amount, and fine filtering with 0.22 micron filtering membrane. The brain protein hydrolysate for injection may be further freeze dried to obtain freeze dried brain protein hydrolysate preparation. The production process is environment friendly, high in yield and low in cost.

The invention relates to a method for preparing a cubilose extract, which comprises the step of adding protease to a cubilose raw material to hydrolyze water-soluble cubilose protein, wherein the addition amount of the protease is 4500-40,000U per 100g water-soluble cubilose protein. The invention further relates to an application of the cubilose extract obtained by the method in preparing cosmetics or health care products.

The invention relates to a method for preparing bonito stick protein hydrolysate with an effect of reducing uric acid. The method comprises the following main steps of raw material heat treatment, restriction digestion, membrane separation-anion exchange chromatography-gel filtration chromatography separation, concentration and spray drying so as to obtain the bonito stick protein hydrolysate with an effect of reducing uric acid. The amino acid analysis indicates that the zymolyte peptide fragment primary amino acid sequence contains four amino acids, namely histidine, arginine, lysine and threonine, the total mass content of the four amino acids is 70 percent of the total amino acid content of zymolyte. MALDI-TOF-MS mass spectrum determines that the molecular weight of the main peptide effective ingredient is less than 700Da. In-vitro uric acid reduction experiments prove that the bonito stick protein hydrolysate has a remarkable effect of inhibiting generation of uric acid, and has an inhibition rate over 50 percent; an oteracil potassium molded hyperuricemic rat animal model indicates that the bonito stick protein hydrolysate can be used for remarkably reducing the level of serum uric acid and serum creatinine of rats, and shows a relatively good kidney protecting effect.

The invention discloses a mytilus edulis enzymolysis polypeptide. The mytilus edulis enzymolysis polypeptide is characterized by containing the following amino acid sequence: Asp Leu Tyr. The mytilus edulis enzymolysis polypeptide is prepared by adopting the following steps of: (1) preparing homogenate from mytilus edulis meat, adding alkaline protease, deactivating the protease, centrifuging, and taking clear solution of the upper layer; (2) performing ultra-filtration on the clear solution, collecting hydrolysate with the molecular weight of below 3K, concentrating, and performing freeze drying; (3) performing chromatographic separation by adopting a DEAE-SepharoseFF ion exchange column; (4) performing chromatographic separation by adopting a Sephadex G-25 gel column; and (5) performing high performance liquid chromatography purification. The invention also discloses application of the mytilus edulis enzymolysis polypeptide prepared by the steps in prostatic cancer resistance. Compared with the prior art, the invention has the advantages that: the mytilus edulis is subjected to enzymolysis and purification by adopting an optimal protease and an optimal technology, a strong cell proliferation inhibiting effect is achieved when the obtained target peptide is applied to prostatic cancer resistant cells, and a feasible research path is provided for resisting prostatic cancer.